Altshuler Shaham’s PTC Therapeutics PTCT Stock Holding History

Altshuler Shaham’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-496	Closed	-$25K	–	575
2022 Q3	$25K	Buy	+496	New	+$24.3K	﹤0.01%	362

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Altshuler Shaham's PTCT Position: Q4 2022 in Review

Altshuler Shaham sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 496 shares — an estimated $25K sold.

Altshuler Shaham first reported a position in PTCT in Q3 2022 and held it in 1 quarter. The position peaked at $25K in Q3 2022. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

Altshuler Shaham reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
Altshuler Shaham sold 496 PTC Therapeutics shares in Q4 2022, an estimated $25K.
Altshuler Shaham first reported a position in PTC Therapeutics in Q3 2022 and held it in 1 quarter.
Altshuler Shaham's PTC Therapeutics position peaked at $25K in Q3 2022.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Altshuler Shaham's 13F filing for Q4 2022, filed 15 Feb 2023.